Bisphosphonate Treatment in Chronic Recurrent Multifocal Osteomyelitis - 07/03/14
Résumé |
Objective |
To test the safety and efficacy of biphosphonates in chronic recurrent multifocal osteomyelitis (CRMO).
Study design |
Five patients with CRMO, all of whom had ongoing pain and loss of function despite conventional treatment with non-steroidal anti-inflammatory agents, were treated with pamidronate (1 mg/kg/dose with a dosing frequency of 2 to 4 monthly for a total treatment duration of 12 to 42 months).
Results |
Pain decreased after the first infusion for 4 of 5 patients, with symptomatic improvement maintained with time. Significant improvement was seen in radiological lesions for these 4 patients.
Conclusion |
Bisphosphonates appear to be a useful and safe adjunctive treatment in CRMO when simple therapies such as anti-inflammatory agents fail to control symptoms or cases in which lesion expansion continues.
Le texte complet de cet article est disponible en PDF.Abbreviations : CNO, CRMO, NSAID, SAPHO syndrome
Plan
Vol 152 - N° 4
P. 571-575 - avril 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?